David Sheyn1, Sangeeta T Mahajan2, Adonis Hijaz3, Emily Slopnick3, Graham Chapman3, Sherif El-Nashar2, Jeffrey M Mangel4. 1. Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Urology, University Hospitals Cleveland Medical Center, 11000 Euclid Avenue, Cleveland, OH, 44106, USA. david.sheyn@uhhospitals.org. 2. Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. 3. Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Urology, University Hospitals Cleveland Medical Center, 11000 Euclid Avenue, Cleveland, OH, 44106, USA. 4. Division of Female Pelvic Medicine and Reconstructive Surgery, Metro Health Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Abstract
OBJECTIVE: To determine if the presence of cerebral white matter disease (WMD) affects the response to anti-cholinergic medications. MATERIALS AND METHODS: This was a retrospective cohort of age-matched patients treated for OAB with anti-cholinergic medications between January 2010 and December 2017. Inclusion criteria were a chief complaint of OAB, never evaluated by a urogynecologist for OAB, treated with a maximum dose for a minimum of 4 weeks, and underwent head computed tomography (CT) within 12 months of starting therapy. Patients with WMD were matched 1:1 by age and number of prior failed antimuscarinics to controls with normal head CTs. Exclusion criteria included incomplete documentation of therapeutic response, non-WMD CT abnormalities, and non-idiopathic OAB. The primary outcome was anti-cholinergic treatment failure. Pairwise analysis between groups was performed using Wilcoxon rank-sum and Fisher's exact test where appropriate. Univariate logistic regression was performed, and any variable that was associated with treatment failure and a p value ≤ 0.2 was included in the multivariable regression analysis. RESULTS: Sixty-eight cases were matched with 68 controls. Patients with WMD were more likely to have undergone hysterectomy (57.4% vs. 41.2%, p = 0.04) and to use diuretics (31.1% vs. 19.1%, p = 0.04). Patients with WMD were more likely to fail treatment compared with controls (60.7% vs. 29.4%, p = 0.004). After adjusting for confounders, WMD was strongly associated with an increased probability of failure (aOR = 7.31, 95% CI: 1.49-12.20). Additional significant risk factors for treatment failure were the previous number of failed medications (aOR = 3.65 per medication, 95% CI: 1.48-9.01) and a rising HbA1c (aOR: 1.39 per 1.0% increase, 95% CI: 1.0-1.91). CONCLUSION: WMD is independently associated with anti-muscarinic treatment failure in women with overactive bladder symptoms.
OBJECTIVE: To determine if the presence of cerebral white matter disease (WMD) affects the response to anti-cholinergic medications. MATERIALS AND METHODS: This was a retrospective cohort of age-matched patients treated for OAB with anti-cholinergic medications between January 2010 and December 2017. Inclusion criteria were a chief complaint of OAB, never evaluated by a urogynecologist for OAB, treated with a maximum dose for a minimum of 4 weeks, and underwent head computed tomography (CT) within 12 months of starting therapy. Patients with WMD were matched 1:1 by age and number of prior failed antimuscarinics to controls with normal head CTs. Exclusion criteria included incomplete documentation of therapeutic response, non-WMD CT abnormalities, and non-idiopathic OAB. The primary outcome was anti-cholinergic treatment failure. Pairwise analysis between groups was performed using Wilcoxon rank-sum and Fisher's exact test where appropriate. Univariate logistic regression was performed, and any variable that was associated with treatment failure and a p value ≤ 0.2 was included in the multivariable regression analysis. RESULTS: Sixty-eight cases were matched with 68 controls. Patients with WMD were more likely to have undergone hysterectomy (57.4% vs. 41.2%, p = 0.04) and to use diuretics (31.1% vs. 19.1%, p = 0.04). Patients with WMD were more likely to fail treatment compared with controls (60.7% vs. 29.4%, p = 0.004). After adjusting for confounders, WMD was strongly associated with an increased probability of failure (aOR = 7.31, 95% CI: 1.49-12.20). Additional significant risk factors for treatment failure were the previous number of failed medications (aOR = 3.65 per medication, 95% CI: 1.48-9.01) and a rising HbA1c (aOR: 1.39 per 1.0% increase, 95% CI: 1.0-1.91). CONCLUSION: WMD is independently associated with anti-muscarinic treatment failure in women with overactive bladder symptoms.
Entities:
Keywords:
Anti-cholinergic; Overactive bladder; White matter disease
Authors: Stasa D Tadic; Derek Griffiths; Werner Schaefer; Andrew Murrin; Becky Clarkson; Neil M Resnick Journal: Neurourol Urodyn Date: 2012-03-30 Impact factor: 2.696
Authors: Alida A Gouw; Alexandra Seewann; Wiesje M van der Flier; Frederik Barkhof; Annemieke M Rozemuller; Philip Scheltens; Jeroen J G Geurts Journal: J Neurol Neurosurg Psychiatry Date: 2010-10-09 Impact factor: 10.154
Authors: J E Simpson; M S Fernando; L Clark; P G Ince; F Matthews; G Forster; J T O'Brien; R Barber; R N Kalaria; C Brayne; P J Shaw; C E Lewis; S B Wharton Journal: Neuropathol Appl Neurobiol Date: 2007-04-18 Impact factor: 8.090
Authors: Vik Khullar; Javier Cambronero; Javier C Angulo; Marianne Wooning; Mary Beth Blauwet; Caroline Dorrepaal; Nancy E Martin Journal: BMC Urol Date: 2013-09-18 Impact factor: 2.264